


Moderna's therapeutics: Checkpoint vaccine (mRNA-4359)

Last program update: May 4, 2022

Modality	Program	ID #	Preclinical development	Phase 1	Phase 2	Phase 3	Commercial	Moderna rights
Systemic secreted & cell surface therapeutics	IL-2 <i>Autoimmune disorders</i>	mRNA-6231	[Progress bar]					Worldwide
	Relaxin <i>Heart failure</i>	mRNA-0184	[Progress bar]					Worldwide
	PD-L1 <i>Autoimmune hepatitis</i>	mRNA-6981	[Progress bar]					Worldwide
Cancer vaccines	Personalized cancer vaccine (PCV)	mRNA-4157	[Progress bar]					50-50 global profit sharing with Merck
	KRAS vaccine	mRNA-4671	[Progress bar]					Worldwide
	Checkpoint vaccine	mRNA-4359	[Progress bar]					Worldwide
Intratumoral Immunology	OX40L/IL-23/IL-36γ (Triplet) <i>Solid tumors/Lymphoma</i>	mRNA-2752	[Progress bar]					Worldwide
	IL-12 <i>Solid tumors</i>	MEDI1191	[Progress bar]					50-50 U.S. profit sharing; AZ to pay royalties on ex-U.S. sales
Localized Regenerative Therapeutics	VEGF-A <i>Myocardial ischemia</i>	AZD8601	[Progress bar]					AZ to pay milestones and royalties
	Propionic acidemia (PA)	mRNA-3927	[Progress bar]					Worldwide
	Methylmalonic acidemia (MMA)	mRNA-3705	[Progress bar]					Worldwide
Systemic Intracellular Therapeutics	Glycogen storage disease type 1a (GSD1a)	mRNA-3745	Open IND [Progress bar]					Worldwide
	Phenylketonuria (PKU)	mRNA-3283	[Progress bar]					Worldwide
Inhaled Pulmonary Therapeutics	Crigler-Najjar syndrome type 1 (CN-1)	mRNA-3351	[Progress bar]					Provided to ILCM free of charge
	Cystic fibrosis (CF)	VXc-522	[Progress bar]					Vertex to pay milestones and royalties

New development program: Checkpoint vaccine to promote anti-checkpoint T-cell responses (mRNA-4359)

- **Program objective:** Stimulate effector T cells that target and kill suppressive immune and cancer cells that express high levels of target checkpoint antigens:
 - Pre-existing IDO- and PD-L1 specific T cells have been identified in cancer patients
 - IDO- and PD-L1-specific T cells can kill immunosuppressive (regulatory) immune cells and cancer cells that overexpress IDO and PD-L1 checkpoints
 - Our vaccine can expand IDO- and PD-L1 specific T cells in pre-clinical models
 - Vaccine induced direct tumor killing can facilitate recognition of tumor-associated antigens by other cytotoxic T cells leading to more tumor killing
 - Systemic PD-1/PD-L1 blockade may further amplify the effect
- **Initial indications:** 1L cutaneous melanoma stage IIIB+ and 1L NSCLC



Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, potential development candidate applications, development candidate activities, preclinical and clinical studies, regulatory submissions and approvals, risk management and estimates, including with respect to the potential market associated with commercial medicines, and forward-looking projections with respect to Moderna or its anticipated future performance or events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new category of medicines such as mRNA, and therefore Moderna’s preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of medicines; and those described in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date referenced on the first page.